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West African countries are currently suffering the most se-
vere pandemic of Ebola virus disease ever recorded, with 
4269 human cases and 2288 deaths (through 6 September 
2014), and the number of cases in the current outbreak ex-
ceeds the number from all previous outbreaks combined. 
Ebola virus disease was first described in 1976 originating 
from the Ebola River in the Democratic Republic of the 
Congo. Five Ebola viruses have been reported to cause 
Ebola virus pandemics, including Zaire Ebola virus, Sudan 
Ebola virus, Ivory Coast Ebola virus, Reston Ebola virus 
and Bundibugyo Ebola virus. The Zaire Ebola virus is the 
most deadly with a fatality rate up to 90%. Unfortunately, 
the current outbreak in the West African countries is caused 
by the Zaire Ebola virus, and no specific treatment for the 
disease is yet available.  
Like other filoviruses, Ebola virus has the special 
thread-like structure seen on electronic micrographs. Ebola 
virion contains a linear, single-stranded negative-sense 
RNA genome, which is approximately 19,000 nucleotides in 
length without a polyadenylated 3′ terminus or a 5′ capped 
end. The genome encodes seven structural proteins and one 
non-structural protein ordered 3′–leader–nucleoprotein 
(NP)–viral protein VP35–VP40–glycoprotein (GP)/secreted 
GP (sGP)–VP30–VP24–RNA-dependent RNA polymerase 
(L)–trailer–5′. The leader and trailer are non-transcribed 
regions but are important signals that control the transcrip-
tion, replication and packaging of the viral genomes into 
new virions. Glycoprotein (GP) is the main viral determi-
nant of Ebola virus pathogenicity.  
The outbreaks of Ebola virus disease have been primarily 
restricted to Africa. This restriction may be because Ebola 
virus disease kills infectors at a high mortality rate and gov-
ernments and individuals always respond quickly to quaran-
tine these areas. The natural reservoir(s) and primary trans-
mission route(s) of Ebola virus disease are not entirely clear. 
It is reported that bats could be a possible reservoir, and 
they may support the replication of Ebola virus without 
symptoms of the disease. Ebola virus disease is believed to 
occur after an Ebola virus is transmitted to a human via 
contact with an infected animal. Human-to-human trans-
mission appears to occur through direct contact with blood 
or other body fluids from infected patients or by contact 
with contaminated medical equipment, so barrier nursing is 
necessary to limit the spread of infection. A report from 
Natural News confirmed that Ebola can be transmitted 
through aerosols and that the virus can survive for days out-
side a host (http://www.naturalnews.com).      
The incubation period of Ebola virus ranges from 2 to 21 
days (http://www.cdc.gov/vhf/ebola/symptoms/index.html). 
 Zhong Y, et al.   Sci China Life Sci   October (2014) Vol.57 No.10 983 
The abrupt onset of Ebola hemorrhagic fever resembles the 
common flu with clinical symptoms, such as fever, head-
ache, sore throat, weakness, myalgia, abdominal pain, diar-
rhea, and vomiting. Haemorrhagic manifestations arise dur-
ing the peak of the illness. The liver, kidney, and spleen are 
damaged by the Ebola virus, leading to serious bleeding and 
coagulation abnormalities, including gastrointestinal bleed-
ing and a range of hematological irregularities, such as 
lymphopenia and neutrophilia. When the virus attacks retic-
uloendothelial cells, cytokines are over produced and cause 
an exaggerated inflammatory response that is not protective. 
The microvascular endothelial cells are eventually infected 
by the Ebola virus, and the vascular integrity is destroyed. 
The terminal stages of Ebola virus infection usually include 
diffuse bleeding, and hypotensive shock accounts for many 
Ebola virus fatalities.  
Until now, we have had no effective vaccines or treat-
ments for Ebola virus. Therefore, comprehensive treatment 
including supportive therapy is most important, such as 
balancing fluids and electrolytes, maintaining oxygen levels, 
and injecting anticoagulants. However, several prospective 
treatment methods are being studied. rNAPc2, nema-
tode-derived anticoagulation protein, has shown 33% effi-
cacy in the treatment of macaque infected with Zaire Ebola 
virus. It plays an important role in weakening coagulation 
and inflammatory [1]. T-750 (favipiravir) is a pyrazinecar-
boxamide derivative and inhibits influenza virus replication. 
T-750 is being tested in the late clinical stage, and it seems 
to effectively treat Ebola virus disease in a mouse model. 
Favipiravir can be converted to T-705-ribofuranosyl-50- 
triphosphate, a nucleotide analog that can inhibit the viral 
RNA-dependent RNA polymerase or induce lethal muta-
genesis by incorporating into the viral RNA [2]. BCX-4430, 
a new nucleotide analogues, inhibits virus replication by 
inhibiting viral RNA polymerase function. It exhibits 
broad-spectrum antiviral activity against numerous viruses, 
including flaviviruses, bunyaviruses, and coronaviruses [3]. 
The serum of recovered patients may also be useful to de-
velop a treatment for Ebola virus disease. During this out-
break of Ebola virus in the West African countries, two 
Americans became infected, and they benefited from a 
cocktail antibody treatment, called ZMapp, which is a mix-
ture of three humanized mouse monoclonal antibodies 
(c13C6, h-13F6, and c6D8). The three anti-Ebola virus 
monoclonal antibodies had significantly protected rhesus 
macaques from a lethal challenge of Ebola virus [4]; how-
ever, no human safety studies were performed before the 
drug was administered to these two patients. The FDA has 
approved ZMapp for the treatment of patients infected with 
Ebola virus in the current emergency situation. The anti-
sense technology can also be used to treat Ebola virus dis-
ease. Warren et al. [5] reported that small interfering RNAs 
and phosphorodiamidate morpholino oligomers may effec-
tively prevent Ebola virus disease in nonhuman primates by 
targeting the Zaire Ebola virus RNA polymerase L protein. 
Based on this technology, TKM-Ebola has also been ap-
proved by the FDA to treat patients infected with Ebola 
virus. However, these experimental treatments have no rec-
orded human safety trials. Some drugs approved for human 
use for other indications, including chloroquine [6], estro-
gen receptor (clomiphene and toremifene) [7], ion channel 
blocker (amiodarone, dronedarone and verapamil) [8] and 
imatinib [6], have shown activity against Ebola virus infec-
tion or entry in vitro or in rodent models. These drugs 
would be candidates for treating EHF, alone or in combina-
tion with other antiviral drugs. 
The common, broad-spectrum, antiviral drug Ribavirin 
might only be effective among moderately ill patients, sim-
ilar to Crimean-Congo hemorrhagic fever (CCHF). Ribavi-
rin is a synthesized guanosine analog that may inhibit RNA- 
dependent RNA polymerase, mutagenize the genome and 
inhibit inosine monophosphate dehydrogenase (IMPDH), 
which is a key enzyme for de novo purine nucleotide bio-
synthesis [9]. In addition to anti-viral treatments, we could 
also consider medicines that provide vascular protection. 
Rutin, or vitamin P, is a major flavonoid that can be used in 
CCHF and epidemic hemorrhagic fever to protect vascular 
barrier integrity. Cell adhesion molecules (CAMs), includ-
ing selectin, intercellular adhesion molecule-1 (ICAM-1) 
and vascular cell adhesion molecule-1 (VCAM-1), play 
critical roles in cell adhesion to the vascular endothelium 
resulting in extravasation of cells and vascular inflammation. 
Rutin can inhibit the expression of CAMs, thus inhibiting 
the adhesion and migration of leukocytes and affecting 
vascular barrier integrity [10,11]. Vitamin C, or ascorbic 
acid, can also be used in CCHF and epidemic hemorrhagic 
fever [11]. It may prevent the endothelial dysfunction via 
stimulating endothelial proliferation, modulating blood flow 
by sparing endothelial cell-derived nitric oxide and increas-
ing the level of type IV collagen in the basement membrane 
[12]. High-dose methylprednisolone also effectively treats 
patients with CCHF [13]. Activation of NF-B could up-
regulate the proinflammatory cytokines followed by endo-
thelial cell dysfunction. Research showed that blockade of 
NF-B activation preserved endothelial barrier integrity. 
Patel et al. [14] reported that statins had the role of an-
ti-inflammatory and immunomodulatory by downregulating 
expression levels of NF-B, sCD40L and sICAM. In addi-
tion, it can also decrease expression of tissue factor and 
thrombin and increase activation of thrombomodulin [15]. 
Currently, statins have been used in the treatment of cardi-
ovascular disease, which could be considered for treating 
patients with EHF.  
Ebola virus disease is a painful reminder, all individuals 
who have been to the infected area should be isolated for at 
least two weeks. To prepare for the Ebola virus pandemic, 
besides detection materials, we should store enough drugs 
specific to Ebola virus disease and commonly used drugs 
for hemorrhagic fever.  
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